| Market Capitalization (Millions $) |
974 |
| Shares
Outstanding (Millions) |
74 |
| Employees |
130 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-265 |
| Cash Flow (TTM) (Millions $) |
-8 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Moonlake Immunotherapeutics is a biotechnology company that focuses on developing innovative immunotherapeutic therapies for cancer. They are a rising star in the biotech industry and have gained global attention for their groundbreaking research.
The company is based in San Francisco, California, and was founded in 2019 by a team of seasoned scientists and business professionals. The team at Moonlake is driven by a shared vision to improve cancer treatment outcomes by harnessing the power of the immune system.
Moonlake's proprietary technology platform is built on a deep understanding of the complex interaction between the immune system and cancer cells. The platform is designed to identify and target specific cancer cells, while leaving healthy cells untouched. This approach minimizes harmful side effects and allows for higher treatment effectiveness. The technology is based on four pillars: T cell activation, immune system modulation, targeted cell death, and antigen targeting.
Moonlake's lead development program is focused on a novel technology called the Multi-Mode Intracellular Targeting (MMIT) Platform. This technology is designed to specifically target and destroy cancer cells, while leaving normal cells unharmed. It works by delivering a unique combination of signaling molecules within cancer cells, leading to apoptosis, or programmed cell death. The MMIT technology has been shown to be effective in a broad range of cancer types.
In addition to the MMIT platform, Moonlake is also pursuing other innovative approaches to treating cancer. These include CAR-T cell therapy, antibody-drug conjugates, and cancer vaccines. The company's goal is to develop a diverse portfolio of novel therapies that can be used in combination with each other to improve patient outcomes.
In summary, Moonlake Immunotherapeutics is a cutting-edge biotechnology company that is pioneering the development of innovative immunotherapeutic cancer treatments. Their unique technology platform and diverse portfolio of therapies have the potential to revolutionize cancer treatment and improve patient outcomes.
Company Address: Dorfstrasse 29 Zug 6300
Company Phone Number: 415108022 Stock Exchange / Ticker: NASDAQ MLTX
|
